Evidence review · from the 250-topic plan

Adolescent GLP-1s: what's approved at twelve-plus, what's different — and the bright line this site draws

What's actually approved

The label map, plainly: semaglutide 2.4 mg (Wegovy) — approved for adolescents 12–17 with obesity, on the same titration architecture as adults; an older, less potent daily agent (liraglutide) preceded it in the age group; and tirzepatide carries no adolescent indication as of this writing — its dedicated adolescent trials are underway, and this page's dateline governs: verify the current label rather than a forum. The regulatory asymmetry matters practically: for a teen, the evidence-and-label conversation currently runs through semaglutide.

The adolescent evidence

The pivotal adolescent trial randomized teens with obesity to weekly semaglutide or placebo atop lifestyle therapy for 68 weeks: BMI fell around 16% on average versus roughly no change with placebo — an effect size in the adult class's neighborhood, with cardiometabolic markers moving alongside and the familiar GI-forward tolerability profile. Context that reframes the whole question: adolescent obesity tracks powerfully into adult disease, earlier bariatric surgery was long the only intervention with results this size, and the AAP's 2023 clinical guideline — the pediatric establishment's document — moved to “treat early and intensively,” naming pharmacotherapy as a legitimate consideration at twelve-plus rather than a last resort. This is the least fringe corner of the field, whatever the comment sections say.

What's different under eighteen

Four honest differences. Growth is in the room: a developing body means monitoring stature, development, and nutrition adequacy — appetite suppression during growth years is managed, not assumed. Family-based care isn't optional: the trials embedded lifestyle therapy and the guidelines demand it; a teen can't run the protein-and-training floor or the comfort protocol against a household's grain. Eating-disorder vigilance doubles: adolescence is ED biology's launch window, so screening before and monitoring during are heavier duties here — appetite medication in a teen with unrecognized disordered eating is the outcome everyone screens to avoid. The horizon is honest: a 14-year-old responder faces potential decades of therapy, and decades of data don't exist yet; the withdrawal literature's regain lesson applies with a longer runway attached. None of these are arguments against treatment — they're the shape of doing it properly, which is the segue this file was built for.

The bright line

This site compares adult cash-pay telehealth, and here's the paragraph that explains why the adolescent lane is excluded from every ranking we publish: proper adolescent treatment is pediatric specialty medicine — growth monitoring, family integration, ED screening, in-person components — none of which survives a checkout quiz. So the consumer-protection rule, stated at field-manual strength: an online seller willing to ship compounded GLP-1s to a minor on quiz-intake is disqualified on contact — it's flags 1-through-3 compounded by a vulnerable population, and “but the label allows twelve-plus” makes it worse, not better: the label allows Wegovy under pediatric care, not gray-market vials under a birthday checkbox. Parents reading this: the legitimate path exists and is below; the shortcut isn't one.

Real-world access, for families

The route that works: start with the pediatrician; ask about pediatric obesity-medicine programs (children's hospitals increasingly run dedicated clinics — multidisciplinary teams built for exactly the differences above); expect intensive lifestyle therapy as the foundation with medication as an adjunct where criteria fit; and budget realism about coverage — pediatric weight-pharmacotherapy coverage is patchy, prior-auth-heavy, and worth the appeal machinery where a chart supports it (adolescent comorbidities — prediabetes, apnea, fatty liver — are exactly the reframing levers). What this site contributes to that journey is what it contributes everywhere: the literacy files travel (nausea, protein, plateaus, family meals), even though our provider rankings deliberately don't. Adult care, done properly ↗

FAQ

Can teenagers take Wegovy or Zepbound?

Wegovy is FDA-approved at 12+ with ~16% average BMI reduction in its adolescent trial; tirzepatide has no adolescent indication as of this writing (trials underway) — and either belongs in pediatric specialty care, not telehealth checkouts.

Is medication for teen obesity recommended by pediatricians?

The AAP's 2023 guideline endorses considering pharmacotherapy at 12+ alongside intensive lifestyle treatment — a deliberate shift from watch-and-wait.

What's different about GLP-1 treatment for adolescents?

Growth and development monitoring, mandatory family-based care, doubled eating-disorder screening, and honest long-horizon counseling — the shape of pediatric specialty medicine.

Can my teen get compounded GLP-1s online?

Any seller willing to do that on quiz-intake is disqualified on contact — adolescent treatment requires pediatric care the checkout model cannot provide.

Sources

• Wegovy adolescent indication and the STEP TEENS trial results.
• AAP 2023 clinical practice guideline on pediatric obesity.
• Tirzepatide adolescent trial registrations — status as of this writing.
• Pediatric obesity-medicine program frameworks; ED-screening practice.